A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Summary

Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a vasoconstrictor that may restore proper circulation and kidney function in patients with HRS.

Timeline

Start

2014-03

Primary completion

2015-11

Completion

2015-12

Drugs

Indications